The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global artificial organs market reached a value of US$ 15.9 Billion in 2020. Looking forward, IMARC Group expects the market to reach a value of US$ 27.2 Billion by 2026, exhibiting a CAGR of 9.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Artificial organs are engineered devices implanted in a human body to replicate the functions of a healthy organ or perform a specific function. They are composed of plastic seeded with stem cells from the transplant recipient. Due to this, the immune system of the body does not reject the artificial organ. They do not require continuous tethering to a power supply or any other stationary resource to keep patients with serious organ failure alive for years.
The global artificial organs market is primarily driven by the increasing number of people suffering from organ failures, especially the aging population, due to severe health conditions, such as diabetes, heart disorders, and chronic kidney diseases. The frequent occurrence of road accidents and injuries leading to amputations have also increased the demand for artificial organs. Besides this, the growing public awareness about advancements in medical technology and improvements in the existing healthcare infrastructure hasled to the development of advanced artificial support systems. Moreover, the introduction of 3D bioprinting and the integration of artificial intelligence (AI) in the production of artificial devices are providing a positive outlook to the market. On the other hand, the high implantation cost and limited surgical expertise in most regions are expected to restrain the market growth. However, the unavailability and shortage of organ donors at the time of requirement have encouraged the development of artificial organ technology across the globe.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial organs market, along with forecasts at the global and regional level from 2021-2026. Our report has categorized the market based on type.
Breakup by Type:
Amongst these, artificial kidneys represent the largest product type.
On a regional basis, North America exhibits a clear dominance in the market.
The competitive landscape of the market has also been analyzed, with some of the key players being Abiomed Inc., Edwards Lifesciences Corp, HeartWare International, Inc., Cochlear Limited, and Boston Scientific Corporation.
This report provides a deep insight into the global artificial organs market, covering all its essential aspects. This ranges from macro-overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the artificial organs industry in any manner.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Abiomed Inc., Edwards Lifesciences Corp, HeartWare International, Inc., Cochlear Limited, and Boston Scientific Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at